X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUN PHARMA AJANTA PHARMA/
SUN PHARMA
 
P/E (TTM) x 24.5 25.1 97.7% View Chart
P/BV x 10.1 3.7 275.8% View Chart
Dividend Yield % 0.6 0.6 94.7%  

Financials

 AJANTA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
SUN PHARMA
Mar-17
AJANTA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720842 204.3%   
Low Rs1,103572 192.7%   
Sales per share (Unadj.) Rs194.6131.6 147.9%  
Earnings per share (Unadj.) Rs45.232.7 138.3%  
Cash flow per share (Unadj.) Rs50.338.0 132.4%  
Dividends per share (Unadj.) Rs8.003.50 228.6%  
Dividend yield (eoy) %0.60.5 114.5%  
Book value per share (Unadj.) Rs132.0152.7 86.5%  
Shares outstanding (eoy) m88.772,399.26 3.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.35.4 135.0%   
Avg P/E ratio x31.221.6 144.3%  
P/CF ratio (eoy) x28.118.6 150.7%  
Price / Book Value ratio x10.74.6 230.8%  
Dividend payout %17.710.7 165.3%   
Avg Mkt Cap Rs m125,2991,696,877 7.4%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m2,57049,023 5.2%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m17,275315,784 5.5%  
Other income Rs m1666,232 2.7%   
Total revenues Rs m17,442322,016 5.4%   
Gross profit Rs m5,807100,893 5.8%  
Depreciation Rs m45112,648 3.6%   
Interest Rs m493,998 1.2%   
Profit before tax Rs m5,47490,479 6.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46012,116 12.0%   
Profit after tax Rs m4,01478,462 5.1%  
Gross profit margin %33.631.9 105.2%  
Effective tax rate %26.713.4 199.2%   
Net profit margin %23.224.8 93.5%  
BALANCE SHEET DATA
Current assets Rs m7,639329,537 2.3%   
Current liabilities Rs m2,715178,870 1.5%   
Net working cap to sales %28.547.7 59.7%  
Current ratio x2.81.8 152.7%  
Inventory Days Days4379 54.7%  
Debtors Days Days7983 94.5%  
Net fixed assets Rs m6,914204,766 3.4%   
Share capital Rs m1772,399 7.4%   
"Free" reserves Rs m11,442363,997 3.1%   
Net worth Rs m11,721366,397 3.2%   
Long term debt Rs m14914,361 1.0%   
Total assets Rs m14,814614,102 2.4%  
Interest coverage x112.923.6 477.9%   
Debt to equity ratio x00 32.4%  
Sales to assets ratio x1.20.5 226.8%   
Return on assets %27.413.4 204.2%  
Return on equity %34.221.4 159.9%  
Return on capital %46.524.8 187.3%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42244,118 23.6%   
Fx outflow Rs m1,67824,484 6.9%   
Net fx Rs m8,74419,634 44.5%   
CASH FLOW
From Operations Rs m3,26470,822 4.6%  
From Investments Rs m-2,093-42,216 5.0%  
From Financial Activity Rs m-1,186-22,854 5.2%  
Net Cashflow Rs m-156,107 -0.2%  

Share Holding

Indian Promoters % 73.8 63.7 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.1 30.2%  
FIIs % 7.6 23.0 33.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.3 204.8%  
Shareholders   20,968 133,026 15.8%  
Pledged promoter(s) holding % 4.4 0.5 828.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Volatile; IT Stocks Lead Gains(01:30 pm)

After opening the day flat, share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - ABBOTT INDIA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS